Item 7.01 Other Events




On January 22, 2021, Aurinia Pharmaceuticals Inc. announced that the U.S. Food
and Drug Administration had approved LUPKYNIS (voclosporin) in combination with
a background immunosuppressive therapy regimen to treat patients with active
lupus nephritis. A copy of the associated press release and investor
presentation are attached as exhibits to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K, including Exhibits 99.1 and
99.2 attached hereto, are being furnished and shall not be deemed "filed" for
the purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that section, nor shall they be
deemed incorporated by reference into any of our filings under the Securities
Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended,
whether made before or after the date hereof, regardless of any general
incorporation language in such filing. The furnishing of this information hereby
shall not be deemed an admission as to the materiality of any such information.
The information contained in the press release and investor presentation is
summary information that is intended to be considered in the context of our
Securities and Exchange Commission filings and other public announcements that
we may make, by press release or otherwise, from time to time. We undertake no
duty or obligation to publicly update or revise such information, except as
required by law.

--------------------------------------------------------------------------------




Item 9.01 Financial Statements and Exhibits
(d) Exhibits.

Exhibit No.                                                Title
                       Press release, dated     January     2    2    , 202    1, related to receipt of
  99.1               FDA approval for LUPKYNIS
  99.2                 Aurinia's Investor Presentation,     dated January     25    , 2021



             Cover Page Interactive Data File (the cover page XBRL tags are embedded within
104          the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses